Syncom Formulations (India) Limited share price

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, s…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: SYNCOMFISIN INE312C01025

16 Oct 2026, 3:30 PM IST₹21.95▲ 0.39 (1.81%)

Market Cap₹ 2,063 Cr.
Current Price₹ 21.95
High / Low₹ 27 / 10
Stock P/E23.4
Book Value₹ 4
Dividend Yield0.46 %
ROCE23.7 %
ROE20.20 %
Face Value₹ 1.0

More figures (10)

EPS (TTM)₹ 0.94
Price / Book4.93
OPM16.1 %
Debt / Equity0.00
Sales growth (3Y)29.7 %
Profit growth (3Y)56.2 %
Promoter holding50.6 %
EV / EBITDA23.0
Beta0.83
All-time high₹ 28

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
SYNCOMF	+19.23%	+60.22%	+57.35%	+53.93%	+33.52%	+34.84%	—
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Syncom Formulations (India) Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹2,063 crore.
It trades at 23.4 times its last 12 months' earnings and 4.9 times book value.
Revenue grew 29.7% a year over the last 3 years, profit 56.2% a year.
Return on equity was 20.2% and return on capital employed 23.7% in the latest year.
Debt was 0.00 times shareholders' equity.
The share price is 20.2% below its 52-week high and up 33.5% over one year.
Promoters and insiders hold about 50.6%; institutions about 0.1%.

Pros

Company is almost debt-free (debt is 0.00 times equity).
Sales have grown 29.7% a year over the last 3 years.
Profit has grown 56.2% a year over the last 3 years.
Healthy return on equity of 15.1% on average over the last 3 years.
Trades at 23.4 times earnings, below its 3-year median of 33.8.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Syncom Formulations (India) Limited

Employees: 902
Head office: Indore

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Syncom Formulations (India)	21.95	23.4	2,063	0.46	25	57.71	126	7.38	23.7	20.2	4.93	16.1	0.00	50.57	489	29.7
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 41 Co.	1,712.85	30.8	23,878	0.35	679	24.47	5,999	18.81	16.4	16.2	4.55	16.9	0.21	53.40	20,499	13.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	60	64	65	75	87	102	128	149	117	122	115	135	126
YOY Sales Growth %				22.29%	45.82%	60.27%	95.78%	99.64%	33.98%	18.96%	-9.72%	-9.04%	7.38%
	53	57	58	65	77	90	113	131	101	103	94	113	99
Material Cost %	59%	61%	61%	57%	62%	64%	68%	67%	59%	58%	53%	62%	52%
Employee Cost %	13%	14%	15%	12%	11%	12%	11%	10%	14%	14%	15%	13%	14%
Other Expenses %	17%	15%	13%	18%	14%	12%	10%	11%	14%	13%	13%	10%	13%
Operating Profit	6	6	7	9	10	12	15	18	16	18	21	22	26
OPM %	11%	10%	11%	13%	12%	12%	12%	12%	14%	15%	18%	16%	21%
	2	4	5	3	1	4	4	7	6	5	6	15	8
Exceptional items			-0					0	0			-0
Interest	1	1	1	1	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	2	2
Profit before tax	6	8	9	10	10	15	17	23	20	22	25	34	32
	28%	23%	25%	26%	24%	25%	25%	24%	22%	25%	25%	25%	23%
Current tax	2	1	2	3	2	4	4	5	4	5	6	7	7
Deferred tax	-0	0	0	0	0	0	0	1	0	0	0	1	0
	4	7	7	7	8	11	13	18	16	17	19	25	25
YOY Profit Growth %				-12.62%	73.61%	70.59%	85.70%	138.97%	106.41%	49.45%	45.42%	42.27%	57.71%
EPS in Rs	0.07	0.08	0.09	0.10	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.27	0.26
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	59	62	63	73	87	101	127	148	117	121	115	134	125
YOY Sales Growth %				19.39%	46.27%	62.68%	100.54%	102.64%	34.22%	19.65%	-9.79%	-9.74%	6.96%
	53	56	57	64	76	90	112	131	101	103	93	113	99
Material Cost %	60%	61%	61%	58%	63%	65%	68%	68%	59%	58%	53%	62%	53%
Employee Cost %	13%	14%	15%	12%	11%	12%	11%	10%	14%	14%	15%	13%	14%
Other Expenses %	17%	14%	12%	18%	14%	11%	9%	11%	14%	12%	13%	9%	13%
Operating Profit	6	6	7	9	10	12	15	17	16	19	21	21	26
OPM %	10%	10%	11%	12%	12%	12%	11%	12%	14%	15%	18%	16%	21%
	2	4	4	3	1	4	4	7	6	5	5	14	8
Exceptional items			-0			-0		0	0			-0
Interest	1	1	1	1	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	2	2
Profit before tax	6	8	9	9	10	15	17	23	20	22	25	33	32
	27%	24%	25%	27%	24%	25%	24%	24%	22%	25%	25%	25%	23%
Current tax	2	1	2	2	2	3	4	5	4	5	6	7	7
Deferred tax	-0	0	0	0	0	0	0	1	0	0	0	1	0
	4	6	6	7	8	11	13	18	16	17	19	25	25
YOY Profit Growth %				-20.29%	79.56%	76.46%	99.22%	159.35%	106.19%	53.80%	47.47%	40.41%	56.33%
EPS in Rs	0.07	0.08	0.09	0.09	0.11	0.16	0.14	0.16	0.21	0.18	0.23	0.26	0.26
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	224	263	465	489	498
YOY Sales Growth %		17.45%	76.55%	5.20%
	205	234	411	412	410
Material Cost %	63%	60%	66%	58%	56%
Employee Cost %	12%	13%	11%	14%	14%
Other Expenses %	17%	16%	11%	12%	12%
Operating Profit	20	30	54	77	88
OPM %	9%	11%	12%	16%	18%
	15	14	17	31	33
Exceptional items	0	-0	0	0	-0
Interest	3	4	1	1	1
Depreciation	5	5	5	7	7
Profit before tax	27	34	66	101	113
	24%	25%	25%	24%	24%
Current tax	7	8	15	23
Deferred tax	-0	1	1	2
	20	25	49	76	86
YOY Profit Growth %		26.13%	95.28%	54.62%
EPS in Rs	0.24	0.34	0.57	0.81	0.94

Compounded Sales Growth

3 Years:: 30%
TTM:: 0%

Compounded Profit Growth

3 Years:: 56%
TTM:: 49%

Stock Price CAGR

3 Years:: 35%
1 Year:: 34%

Return on Equity

4 Years:: 13%
Last Year:: 20%

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	225	258	463	487	495
YOY Sales Growth %		15.01%	79.15%	5.13%
	205	231	409	409	407
Material Cost %	63%	60%	66%	58%	57%
Employee Cost %	12%	14%	11%	14%	14%
Other Expenses %	16%	15%	11%	12%	12%
Operating Profit	20	28	54	77	87
OPM %	9%	11%	12%	16%	18%
	15	13	17	31	33
Exceptional items	0	-0	0	0	-0
Interest	3	4	1	1	1
Depreciation	5	5	5	7	7
Profit before tax	27	32	65	101	112
	24%	26%	24%	24%	24%
Current tax	7	8	14	23
Deferred tax	-0	1	1	2
	20	24	49	76	85
YOY Profit Growth %		17.70%	106.88%	55.53%
EPS in Rs	0.24	0.32	0.57	0.81	0.93
Dividend Payout %	14%

Compounded Sales Growth

3 Years:: 29%
TTM:: 0%

Compounded Profit Growth

3 Years:: 56%
TTM:: 49%

Stock Price CAGR

3 Years:: 35%
1 Year:: 34%

Return on Equity

4 Years:: 13%
Last Year:: 20%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	94	94	94	94
Reserves	162	194	248	321
	83	72	5	1
Short term borrowings	83	72	5	1
	39	44	67	117
Trade payables	20	24	44	74
Current liabilities	113	107	59	104
Total Liabilities	378	405	413	534
	71	73	78	91
Gross block	129	135	145	157
Accumulated depreciation	58	63	67	66
Goodwill & intangibles	0	0	0	0
CWIP	27	0	1	1
	280	332	335	442
Inventories	21	21	41	63
Trade receivables	76	103	108	111
Cash & equivalents	1	63	1	5
Current assets	182	275	270	330
Total Assets	378	405	413	534

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	11	-6	23	58
Profit for the year	20	25	49	76
Working capital changes	-3	-28	-16	10
Direct taxes paid	-7	-8	-15	-23
	-45	83	-18	-51
Fixed assets purchased	-21	-8	-10	-12
	35	-15	-68	-3
Interest paid	-3	-4	-1	-1
Dividends paid	-3
Net Cash Flow	1	63	-63	4
Free Cash Flow	-10	-14	13	46

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	7.8%	9.3%	15.7%	20.2%
ROCE	—	11.2%	12.8%	18.7%	23.7%
Operating margin	—	7.4%	9.7%	11.8%	16.1%
Net margin	—	9.0%	9.8%	10.8%	15.9%
Debt / equity	—	0.32	0.25	0.01	0.00
Current ratio	—	1.61	2.58	4.55	3.18
Debtor days	—	124	145	86	84
Inventory days	—	52	47	48	78
Days payable	—	50	53	51	92
Cash conversion cycle	—	126	139	83	70
Working capital days	—	112	237	168	172

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 50.57%
FIIs 2.22%
Public 47.20%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%	50.57%
		0.08%	0.09%	0.10%	0.13%	0.11%	0.41%	0.10%	0.26%	0.21%	0.35%	2.22%
Foreign portfolio investors (Cat. I)		0.08%	0.09%	0.10%	0.13%	0.11%	0.41%	0.10%	0.26%	0.15%	0.22%	0.65%
Foreign portfolio investors (Cat. II)										0.06%	0.13%	1.58%
	49.43%	49.35%	49.34%	49.33%	49.30%	49.32%	49.02%	49.33%	49.17%	49.21%	49.08%	47.20%
Retail (up to ₹2 lakh)	36.72%	37.14%	38.28%	39.16%	39.06%	39.15%	38.50%	38.56%	38.63%	38.75%	38.39%	35.93%
HNIs (above ₹2 lakh)	8.10%	7.71%	6.79%	5.99%	6.00%	6.05%	6.33%	6.65%	6.41%	6.41%	6.50%	6.44%
NRIs	1.89%	1.87%	1.76%	1.73%	1.76%	1.75%	1.79%	1.80%	1.80%	1.81%	1.81%	1.77%
Bodies corporate	1.45%	1.28%	1.04%	1.12%	1.09%	1.02%	1.10%	1.00%	0.98%	0.96%	1.01%	1.38%
IEPF	0.15%	0.22%	0.22%	0.22%	0.27%	0.27%	0.27%	0.27%	0.27%	0.26%	0.25%	0.25%
No. of Shareholders	2,89,982	3,25,761	3,76,530	4,69,242	4,89,520	4,84,529	4,71,066	4,57,364	4,42,280	4,31,690	4,22,114	4,18,465

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

None filed recently.

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 23 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Syncom Formulations (India) Limited

What is the share price of Syncom Formulations (India) Limited today?

Syncom Formulations (India) Limited (SYNCOMF) last traded at ₹21.95 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Syncom Formulations (India) Limited?

About ₹2,063 crore at the latest price.

What is the P/E ratio of Syncom Formulations (India) Limited?

About 23.4 times its earnings over the last 12 months.

Is Syncom Formulations (India) Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Syncom Formulations (India) Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Syncom Formulations (India) Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Syncom Formulations (India) Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Syncom Formulations (India) Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next